1. Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults
- Author
-
Antonio Javier Blasco, Rafael Rubio, Montserrat Tuset, Jesús Santos, Josep M. Gatell, Fernando Lozano, José López-Aldeguer, Pere Domingo, Eugenia Negredo, Hernando Knobel, Pablo Lázaro, Federico Pulido, Javier de la Torre, Ana Mariño, José M. Miró, José Antonio Iribarren, Santiago Moreno, Esteban Martínez, Miguel A. Von Wichmann, José A. Pérez-Molina, and Jose R. Arribas
- Subjects
0301 basic medicine ,Microbiology (medical) ,Pediatrics ,medicine.medical_specialty ,Cost effectiveness ,Cost ,Sida ,Cost-Benefit Analysis ,030106 microbiology ,effectiveness ,HIV Infections ,Efficiency ,Tratamiento antirretroviral ,03 medical and health sciences ,0302 clinical medicine ,Eficiencia ,Acquired immunodeficiency syndrome (AIDS) ,Virus de inmunodeficiencia humana ,Hiv infected ,Antiretroviral treatment ,Medicine ,Humans ,030212 general & internal medicine ,Costes ,health care economics and organizations ,Acquired Immunodeficiency Syndrome ,biology ,business.industry ,Human immunodeficiency virus ,Euros ,medicine.disease ,biology.organism_classification ,Antiretroviral therapy ,AIDS ,Regimen ,Models, Economic ,Anti-Retroviral Agents ,Spain ,Eficacia ,Guideline Adherence ,business ,Viral load - Abstract
[Background]: The GESIDA/National AIDS Plan expert panel recommended preferred regimens (PR), alternative regimens (AR) and other regimens (OR) for antiretroviral treatment (ART) as initial therapy in HIV-infected patients for 2018. The objective of this study was to evaluate the costs and the efficiency of initiating treatment with PR and AR. [Methods]: Economic assessment of costs and efficiency (cost-effectiveness) based on decision tree analyses. Effectiveness was defined as the probability of reporting a viral load
- Published
- 2019